Yujin Hoshida, MD, PhD, associate professor of internal medicine, University of Texas Southwestern Medical Center, discusses molecular subtyping in hepatocellular carcinoma (HCC).

Over the past decade, multiple subtypes of HCC have been identified using advanced genomic technology, says Hoshida. The research suggests that there may be a link between how patients with different molecular subtypes of HCC respond to different therapeutic options, explains Hoshida.

Understanding what patient subtype responds best to what treatment may be a more efficient way to personalize therapy rather than to direct specific drugs to multiple targets, concludes Hoshida.

Videos

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.



Yujin Hoshida, MD, PhD

Articles

Dr. Hoshida on Molecular Subtyping in HCC